82413-20-5

• 常用中文名：屈洛昔芬
• 常用英文名：Droloxifene
• CAS号：82413-20-5
• 分子式：C₂₆H₂₉NO₂
• 分子量：579.63700
• 相关类别： 原料药 抗肿瘤药 激素类抗肿瘤药
• 发布时间：2018-09-17 11:56:08
• 更新时间：2024-01-02 19:36:58
• Droloxifene,Tamoxifen 衍生物,是一种具有口服活性和选择性的雌激素受体 (estrogen receptor) 调节剂。Droloxifene 具有抗雌激素和抗植入作用。Droloxifene 诱导 MCF-7 细胞 p53 表达及凋亡。Droloxifene 预防去卵巢大鼠骨丢失。

名称

• 中文名: 屈洛昔芬
• 英文名: 3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
• 中文别名: 3-[1-[4-(2-二甲基氨基乙氧基)苯基]-2-苯基丁-1-烯基]苯酚; 屈洛昔酚
• 英文别名: (E)-1-(4'-(2-dimethylaminoethoxy)phenyl)-1-(3-hydroxyphenyl)-2-phenylbut-1-ene; Droloxifenum [Latin]; Droloxifene; K 060; K 060E; MFCD00468089; FK-435; E-1-[4'-(2-dimethylaminoethoxy)-phenyl]-1-(3'-hydroxyphenyl)-2-phenyl-1-butene; E-Droloxifene; Droloxifeno [Spanish]; 3-Hydroxytamoxifen

物化性质

• 密度: 1.092 g/cm3
• 沸点: 526.6ºC at 760 mmHg
• 熔点: 127-129ºC
• 分子式: C₂₆H₂₉NO₂
• 分子量: 579.63700
• 精确质量: 579.24700
• PSA: 164.83000
• LogP: 4.45320
• 外观性状: 灰白色至灰白的-米色固体
• 折射率: 1.596
• 储存条件: Amber Vial, -20°C Freezer

生物活性

• 描述: Droloxifene,Tamoxifen 衍生物,是一种具有口服活性和选择性的雌激素受体 (estrogen receptor) 调节剂。Droloxifene 具有抗雌激素和抗植入作用。Droloxifene 诱导 MCF-7 细胞 p53 表达及凋亡。Droloxifene 预防去卵巢大鼠骨丢失。
• 相关类别:
  信号通路 >> 其他 >> 雌激素受体/ERR
  研究领域 >> 癌症
• 体外研究: Droloxifene(10nm；16-18h)诱导MCF-7细胞凋亡[1]。细胞活力测定[2]细胞株：MCF-7细胞浓度：10nm培养时间：16-18h结果：诱导细胞凋亡
• 体内研究: 屈洛昔芬(5-20 mg/kg；p.o.；每日4周)以10 mg/kg的剂量增加DFM的骨密度,并完全防止20 mg/kg/天的剂量降低去卵巢(OVX)引起的DFM的骨密度和骨密度[3]。动物模型：5月龄假手术大鼠[3]剂量：5、10、20 mg/kg口服；每日4周结果：10 mg/kg时DFM的骨密度显著增加；20 mg/kg/d时完全阻止OVX所致DFM的骨密度和骨密度下降。
• 参考文献:

  [1]. Herrington DM, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthypostmenopausal women. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1606-12.

  [2]. Grasser WA, et al. Common mechanism for the estrogen agonist and antagonist activities of droloxifene. J Cell Biochem. 1997 May;65(2):159-71.

  [3]. Ke HZ, et al. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. ndocrinology. 1995 Jun;136(6):2435-41.

  [4]. Huang Y, et al. Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity. Acta Pharmacol Sin. 2005 Oct;26(10):1243-7.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : SL1209900 CHEMICAL NAME : Phenol, 3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-b utenyl)-, (E)- CAS REGISTRY NUMBER : 82413-20-5 LAST UPDATED : 199704 DATA ITEMS CITED : 7 MOLECULAR FORMULA : C26-H29-N-O2 MOLECULAR WEIGHT : 387.56 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >4500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,186,1984 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >2250 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,186,1984 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >3 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,186,1984 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >1500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,186,1984 *** REVIEWS *** IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 66,241,1996 IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 66,241,1996 IARC Cancer Review:Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 66,241,1996

安全

• 危害码 (欧洲): Xi

合成路线

上下游产品

上游产品  9
83647-29-4 83647-26-1 879893-00-2 40595-34-4
100-66-3 134518-89-1 57999-49-2 75731-44-1
611-81-4
下游产品  0